Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Epitas Biosciences presents IDH2 inhibitors

Nov. 13, 2020

HitGen patents HDAC inhibitors

Nov. 13, 2020

First patient treated in phase I study of MaaT-033

Nov. 13, 2020

Curasight initiates preclinical study of uTREAT therapy in brain cancer

Nov. 13, 2020

Enrollment completed and interim data presented from DRIIV-1b study of AsiDNA

Nov. 13, 2020

China IND approval for Apollomics' multikinase inhibitor APL-102

Nov. 12, 2020

Metabolic pathway-based TNBC subtyping reveals potential new targets

Nov. 12, 2020

Massachusetts Institute of Technology synthesizes compounds for cancer

Nov. 12, 2020

Kuling Therapeutics patents RORC antagonists

Nov. 12, 2020

Early clinical data reported for [177Lu]rhPSMA-7.3 in mCRPC

Nov. 12, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...